Abstract: The present invention relates to a method of identifying a metastatic tumor determined to have a mutation in homologous recombination pathway genes, that is sensitive to treatment with talazoparib, or a pharmaceutically acceptable salt thereof, and methods of treatment thereof, comprising a) determining a homologous recombination deficiency score from a biopsy of the metastatic tumor; and b) administering talazoparib, or a pharmaceutically acceptable salt thereof, if the homologous recombination deficiency score is at least 33%, wherein the mutation is not germline BRCA1 or germline BRCA2. The present invention also relates to a method of selecting a subject determined to have a metastatic tumor with a mutation in homologous recombination pathway genes, for treatment with talazoparib, or a pharmaceutically acceptable salt thereof.

Abstract: Methods to identify modulators of histone acetyltransferases are described. Modulators of histone acetyltransferases can be used to treat individuals. In some instances, modulators of histone acetyltransferases are utilized to treat individuals having a neoplasm.